ImetelChat

Reposted from Paul C on Stocktwits: “ I’m currently on this drug trial in the UK. I was diagnosed 4 years ago low risk watch and wait. 6 months later my bloods dropped and i started on weekly Epo & GCSF injections, these worked for around 18 months. I then began having blood transfusions every 4 wee...

Jay, thanks for posting. We have discussed previously the unholy marriage of industry and medicine without which not much would be happening over on the clinical trials web site. Psychiatry is particularly terrible since they have so little to work with. Almost no one engages in Freudian analysis th...

Just the newer classification system that up’s more patients out of lower risk categories and highlights that there is utility in more advanced classifications going forward. Disease modification again mentioned. I think the subtext is that there is hope that progression to high risk and AML may be ...

Kmall, agree. Geron could support this sales force for 5 years with just the extra burden imposed by the FDA delay.

Thanks for the background, pretty impressive advisory board. Will be interesting to see what their analysis reveals. It appears as a non profit, that they could be self appointed watch dogs to reign in or at least shine a spotlight on excessive medical costs. We really don’t know how Imetelstat will...

Ryan, thanks for posting. Can you give us a primer on who ICER is and would would have commissioned this review (Geron, FDA, Pharmas?). thanks, bp

Wow, that’s a lot of positions. I think these positions are basically for “drug reps” who will call on doctors, hospitals and pharmacists. There are 50 of them. One person can not cover an entire state or other widely defined geography, especially if “50%” of the time they are traveling. Geron is bu...

Geron has added (at expense) many layers of experts including those who specialize in being sure all the FDA t’s are crossed and i’s dotted. MA should be highly likely bolstered by virtually every expert we have heard who makes a point of emphasizing that the grade 3 and 4 cytopenias are actually “o...

Thanks RC. Good presentation with Imet highlights. What is striking to me is the willingness to offer BMT even to prolong life for a few months. An effective treatment agent is what they want especially one that modifies disease. For those who are “concerned/critical” of Imetelstats adverse effects,...

MG, nice! Thanks for sharing and best wishes for the New Year.

2024 should be quite the year for us. Despite recent poorly researched hit articles (be careful where you get your advice, especially here!), 2024 should reveal new AML data, a window into the oral agent development and of course FDA approval. A few recent comments from the experts bear emphasis. I ...

RC either we are missing something or the FDA is. You know who gets my vote.

Nice shout out to Geron from Dr Zeidan for persistence in the face of Janssen hissy fit.

youtu.be/EeqbocpDmGI?si=YiL6A9aQOM6ye-Ce

Dollars and cents:

https://www.valueinhealthjournal.com/ar ... 5/fulltext

CKTC, I was hoping this patent might get your attention. Thanks for sharing your thoughts. I can’t imagine Geron would just roll on this without attempting some agreement on royalties (or merger—time to come home Sergei?) Happy holidays to all. bp

RC, yes, this one is worth a careful listen even though it is very short. Points made: that Lus doesn’t seem to promote the malignant clone was viewed as good news. But no statement as to whether Lus suppresses the malignant clone. Dr. Brenner foresees the day when early disease can be detected and ...